X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3974) 3974
Publication (348) 348
Newsletter (118) 118
Book Review (38) 38
Book Chapter (14) 14
Newspaper Article (12) 12
Magazine Article (5) 5
Report (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3425) 3425
lamivudine (2374) 2374
female (2067) 2067
male (2062) 2062
adult (1864) 1864
index medicus (1743) 1743
middle aged (1442) 1442
lamivudine - therapeutic use (1361) 1361
hiv infections - drug therapy (1193) 1193
antiviral agents - therapeutic use (1152) 1152
hepatitis b (1126) 1126
treatment outcome (1071) 1071
hepatitis b, chronic - drug therapy (1025) 1025
gastroenterology & hepatology (982) 982
infectious diseases (940) 940
drug therapy, combination (843) 843
therapy (804) 804
lamivudine - adverse effects (763) 763
anti-hiv agents - therapeutic use (696) 696
hiv (678) 678
anti-hiv agents - adverse effects (648) 648
hepatitis b virus (630) 630
drug therapy (624) 624
lamivudine - administration & dosage (620) 620
tenofovir (617) 617
pharmacology & pharmacy (604) 604
viral load (599) 599
adenine - analogs & derivatives (598) 598
aged (577) 577
infection (564) 564
antiviral agents (541) 541
reverse transcriptase inhibitors - therapeutic use (533) 533
antiviral agents - adverse effects (529) 529
immunology (528) 528
health aspects (498) 498
hepatitis b virus - genetics (494) 494
virology (476) 476
hepatitis b virus - drug effects (470) 470
adefovir dipivoxil (461) 461
dna, viral - blood (457) 457
antiretroviral therapy (438) 438
hepatitis (426) 426
adolescent (425) 425
care and treatment (420) 420
adenine - therapeutic use (413) 413
risk factors (405) 405
entecavir (404) 404
zidovudine (398) 398
hepatitis b - drug therapy (397) 397
anti-hiv agents - administration & dosage (374) 374
efficacy (370) 370
organophosphonates - therapeutic use (365) 365
antiviral agents - administration & dosage (364) 364
hiv infection (363) 363
time factors (357) 357
cd4 lymphocyte count (355) 355
chronic hepatitis b (353) 353
retrospective studies (349) 349
reverse transcriptase inhibitors - adverse effects (343) 343
hepatitis b, chronic - virology (340) 340
research (336) 336
interferon (331) 331
guanine - analogs & derivatives (326) 326
drug resistance, viral (322) 322
young adult (319) 319
hepatitis b e antigens - blood (317) 317
zidovudine - therapeutic use (316) 316
safety (313) 313
human immunodeficiency virus--hiv (307) 307
hiv infections - virology (303) 303
transplantation (299) 299
analysis (294) 294
combination (285) 285
pregnancy (282) 282
prospective studies (281) 281
resistance (277) 277
dosage and administration (276) 276
drug administration schedule (276) 276
antiretroviral drugs (274) 274
prevention (271) 271
medicine, general & internal (269) 269
reverse transcriptase inhibitors - administration & dosage (262) 262
emtricitabine (260) 260
dna (258) 258
hepatocellular-carcinoma (258) 258
microbiology (258) 258
virus-infection (258) 258
adenine - adverse effects (257) 257
highly active antiretroviral therapy (255) 255
mutation (254) 254
recurrence (250) 250
liver transplantation (249) 249
follow-up studies (247) 247
medicine & public health (246) 246
zidovudine - adverse effects (246) 246
aids (241) 241
hepatitis b surface antigens - blood (241) 241
hepatitis b - prevention & control (240) 240
liver (239) 239
guanine - therapeutic use (238) 238
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3952) 3952
French (38) 38
Chinese (32) 32
German (32) 32
Spanish (28) 28
Japanese (10) 10
Korean (9) 9
Dutch (5) 5
Italian (5) 5
Danish (4) 4
Russian (4) 4
Polish (3) 3
Czech (2) 2
Hungarian (2) 2
Portuguese (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


世界肝病学杂志:英文版(电子版), ISSN 1948-5182, 2017, Volume 9, Issue 5, pp. 227 - 241
Oral nucleoside/nucleotide analogues(NAs) are currently the backbone of chronic hepatitis B(CHB) infection treatment. They are generally well-tolerated by... 
Entecavir | Lamivudine | Nucleoside/nucleotide analogues | Adverse effects | Tenofovir | Adefovir | Side effects | Adverse events | Chronic hepatitis B | Hepatitis B infection | Hepatitis B virus | Safety | Telbivudine | Review | Nucleoside | nucleotide analogues
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Hepatology, ISSN 0270-9139, 06/2014, Volume 59, Issue 6, pp. 2092 - 2100
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2006, Volume 354, Issue 3, pp. 251 - 260
Journal Article
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article